Welcome to our dedicated page for Aspira Womens Health SEC filings (Ticker: AWHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aspira Women's Health Inc. filings document the public-company record for a women's health diagnostics business focused on noninvasive gynecologic disease testing. Recent Form 8-K reports cover executive appointments, laboratory-services agreements, secured borrowing, equity-purchase arrangements, investor-presentation disclosures, and other material events involving the company's common stock and operating relationships.
Proxy materials describe board matters, executive compensation, equity awards, and shareholder voting items. Registration statements and related agreements disclose securities offerings, resale registration matters, common stock terms, filer status, and capital-structure effects. The filing record also includes a Form 12b-25 notice related to timing of the annual report and accounting completion for Aspira's Form 10-K.
Jack W. Schuler and the Jack W. Schuler Living Trust updated their ownership disclosure in Aspira Women's Health Inc. following a new private purchase. On June 5, 2026, the Trust bought 222,222 shares of common stock and a warrant to purchase 300,000 additional shares under a June 2026 Securities Purchase Agreement.
After this transaction, Mr. Schuler reports beneficial ownership of 4,052,587 shares, or 8.7% of Aspira’s common stock, with most shares held through the Trust. The Trust alone reports 4,046,051 shares, or 8.6% of the company, based on 46,800,411 shares outstanding after including recent issuances.
Aspira Women's Health Inc. insider filing shows net buying activity by the Jack W. Schuler Living Trust, for which Jack W. Schuler serves as sole trustee and may be deemed to beneficially own the securities.
On June 5, 2026, the Living Trust purchased 222,222 shares of Common Stock at $0.45 per share and 300,000 Warrants (Right to Buy) for Common Stock with a $0.75 exercise price expiring in 2029. Following these transactions, the trust held 4,046,051 shares of Common Stock indirectly, while Schuler also held 6,536 Common shares and multiple warrant positions directly and indirectly.
Aspira Women’s Health Inc. entered into securities purchase agreements for a private placement of equity and warrants with accredited and institutional investors. The company issued 3,300,000 shares of common stock and common warrants to purchase up to 4,455,000 additional shares at $0.45 per share and accompanying warrant.
The common warrants are exercisable immediately at $0.75 per share and have a three-year term. The private placement closed on June 5, 2026 and generated approximately $1.485 million in gross proceeds, which the company plans to use for working capital and general corporate purposes. Purchasers received customary registration rights for the shares and warrant shares.
Aspira Women's Health director Jeffrey K. Cohen reported changes in his holdings. The main event was an "other" transaction coded J on September 17, 2025, where 11,112 shares of common stock at $0.45 per share were acquired as payment from another party in settlement of another property.
After this, Cohen directly held 386,018 common shares and indirectly held 71,010 shares through his spouse. He also held warrants to buy 450,318 common shares at $0.35 per share expiring on March 5, 2031, and warrants to buy 41,667 shares at $0.75 per share expiring on September 17, 2030.
Aspira Women's Health director Fraser John D filed an amended Form 4 to correct the number of shares indirectly held through Seamark Capital and the presentation of his warrant holdings as of September 17, 2025. He bought 16,389 shares of common stock at $0.45 per share and acquired a warrant for 12,292 underlying shares with a $0.75 exercise price. Following these transactions, he directly owns 566,393 common shares and holds 287,769 shares indirectly via Seamark Capital. He also holds warrants covering 900,633 shares at a $0.35 exercise price expiring in 2031 and 68,627 shares at a $2.25 exercise price expiring in 2027, plus the new warrant for 12,292 shares expiring in 2030.
Aspira Women's Health director Jeffrey K. Cohen reported open-market purchases of common stock and warrants in an amended Form 4. On September 17, 2025, he bought 55,556 shares of common stock at $0.45 per share, bringing his directly held common stock position to 374,906 shares.
He also purchased a warrant covering 41,667 shares of common stock with an exercise price of $0.75 per share, expiring on September 17, 2030, and now holds 41,667 of these warrants directly. Separately, 71,010 shares of common stock are reported as held indirectly through his spouse.
The filing further shows a direct warrant position with an exercise price of $0.35 per share, expiring on March 5, 2031, relating to 450,318 underlying shares of common stock. According to the footnote, this amendment corrects prior disclosures about the number and nature of shares and warrants held on September 17, 2025.
Aspira Women’s Health Inc. entered into a Master Collaboration and License Agreement with Cleveland Clinic Foundation effective May 20, 2026. The companies will jointly pursue biomedical research and development projects, including biomarker discovery and AI-driven diagnostic model development in women’s health.
Aspira will pay Cleveland Clinic a non-refundable, non-creditable partnering fee of $125,000, with $50,000 due within 30 days of the effective date and $25,000 on each of the first three anniversaries. The initial term is five years, with mutual extension rights, and the agreement includes customary provisions on confidentiality, healthcare law compliance, and indemnification.
Aspira Women’s Health Inc. reported Q1 2026 results showing fragile finances despite an accounting profit. Revenue from its OvaSuite diagnostic tests was $1.967M, down from $2.279M a year earlier, and the company recorded a loss from operations of $2.203M.
Net income was $0.676M, driven mainly by a non‑cash $3.11M gain from revaluing warrant liabilities, along with higher interest expense. Cash and cash equivalents were only $1.344M against total liabilities of $11.295M and a working capital deficit of about $1.81M, leading management to state there is “substantial doubt” about its ability to continue as a going concern.
The company was delisted from Nasdaq in 2025 and now trades on the OTC QX Market. To fund operations, it relies on high‑cost debt, including a subordinated loan with a 42% interest rate, and equity facilities such as a $10M purchase agreement with Lincoln Park, of which $7k was used in Q1.
Aspira Women’s Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford, who stepped down for personal reasons. Strahley will work in a fractional role, committing at least twenty hours per week.
Under his Executive Employment Agreement, Strahley receives an annualized base salary of $167,000 and is eligible for the company’s 401(k) plan but not for group insurance benefits. The Board will approve stock options for 70,000 shares at fair market value on the grant date, with 25% vesting ninety days after his start date and the remainder vesting monthly over the following nine months. Any unvested options fully vest upon a Change in Control, and his at-will employment includes no severance beyond accrued obligations.